ACRUX LIMITED - Announcements

0.00%

1.8¢

Market Cap $7.366M

Healthcare Drug Manufacturers - Specialty & Generic

Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is... Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

ACR	Company Update - COVID-19		20/03/20	149.91KB	Share
ACR	Change of Director's Interest Notice		16/03/20	472.7KB	Share
ACR	Appendix 2A		16/03/20	333.56KB	Share
ACR	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	25/02/20	982.5KB	Share
ACR	Change of Director's Interest Notice		17/02/20	250.33KB	Share
ACR	Appendix 2A		17/02/20	336.72KB	Share
ACR	Appendix 3G		04/02/20	339.47KB	Share
ACR	Appendix 2A		04/02/20	336.31KB	Share
ACR	Change of Director's Interest Notice		15/01/20	249.94KB	Share
ACR	Appendix 3B		15/01/20	525.04KB	Share
ACR	Appendix 3B		16/12/19	523.62KB	Share
ACR	Change of Director's Interest Notice		09/12/19	537.7KB	Share
ACR	Appendix 3B		09/12/19	526.67KB	Share
ACR	Initial Director's Interest Notice		28/11/19	215.21KB	Share
ACR	Final Director's Interest Notice		28/11/19	150.02KB	Share
ACR	Annual General Meeting Results		28/11/19	139.75KB	Share
ACR	Acrux Investor Presentation		28/11/19	702.05KB	Share
ACR	Acrux AGM Script		28/11/19	205.14KB	Share
ACR	Receipt of second R&D Tax Incentive Rebate		06/11/19	134.42KB	Share
ACR	2019 Notice of Annual General Meeting		25/10/19	3.22MB	Share
ACR	Receipt of first R&D Tax Incentive Rebate	PRICE SENSITIVE	24/10/19	135.27KB	Share
ACR	Presentation - Australian Microcap Investment Conference		22/10/19	875.88KB	Share
ACR	Change of Director's Interest Notice		07/10/19	195.27KB	Share
ACR	Change of Director's Interest Notice		03/10/19	195.82KB	Share
ACR	Change of Director's Interest Notice		24/09/19	195.45KB	Share
ACR	Annual Report to shareholders		24/09/19	2.09MB	Share
ACR	Notice Received Under S249N of the Corporations Act		23/09/19	135.75KB	Share
ACR	Change of Director's Interest Notice		10/09/19	195.63KB	Share
ACR	Acrux Ltd Investor Presentation and Full Year Results	PRICE SENSITIVE	26/08/19	713.5KB	Share
ACR	Appendix 4G and Corporate Governance Statement		23/08/19	722.47KB	Share
ACR	Appendix 4E & Full Year Statutory Accounts	PRICE SENSITIVE	23/08/19	2.44MB	Share
ACR	Acrux's third generic dossier accepted by FDA for review		19/08/19	216.36KB	Share
ACR	Appendix 3B		15/08/19	1.16MB	Share
ACR	Investor Presentation - Bioshares Summit		29/07/19	906.5KB	Share
ACR	Appendix 3B		17/06/19	1.13MB	Share
ACR	Change in Company Secretary		07/06/19	140.02KB	Share
ACR	Jublia Patent Litigation Settlement	PRICE SENSITIVE	03/04/19	123.89KB	Share
ACR	Becoming a substantial holder		28/02/19	156.57KB	Share
ACR	Investor Presentation	PRICE SENSITIVE	25/02/19	837.85KB	Share
ACR	Appendix 4D and Half-Year Financial Report to 31 Dec 2018	PRICE SENSITIVE	21/02/19	965.44KB	Share
ACR	Appendix 3B		18/02/19	383.01KB	Share
ACR	Appendix 3B		05/02/19	385.91KB	Share
ACR	Acrux Receives $2.057m R&D Tax Incentive Rebate	PRICE SENSITIVE	21/01/19	106.75KB	Share
ACR	End of Year Update		20/12/18	361.75KB	Share
ACR	Appendix 3B		23/11/18	384.11KB	Share
ACR	Change of Director's Interest Notice		13/11/18	157.25KB	Share
ACR	2018 AGM Results		01/11/18	144.16KB	Share
ACR	2018 AGM Script		01/11/18	143.89KB	Share
ACR	2018 AGM Presentation		01/11/18	837.15KB	Share
ACR	Change of Director's Interest Notice		19/10/18	156.7KB	Share
ACR	Acrux has second generic dossier accepted for review by FDA	PRICE SENSITIVE	17/10/18	215.94KB	Share
ACR	Acrux confirms patent challenge for generic of efinaconazole	PRICE SENSITIVE	24/09/18	157.3KB	Share
ACR	Notice of 2018 Annual General Meeting/Proxy Form		21/09/18	336.5KB	Share
ACR	2018 Annual Report		21/09/18	2.69MB	Share
ACR	Updated Acrux Investor Presentation		18/09/18	1.06MB	Share
ACR	2018 Annual Results and Investor Presentation		16/08/18	1.1MB	Share
ACR	Appendix 4G		16/08/18	572.42KB	Share
ACR	Appendix 4E and 2018 Financial Report	PRICE SENSITIVE	16/08/18	1.44MB	Share
ACR	Investor Conference Call 2018 Annual Results		14/08/18	105.31KB	Share
ACR	Acrux Submits First-To-File Generic of Jublia	PRICE SENSITIVE	02/08/18	202KB	Share
ACR	Becoming a substantial holder		10/04/18	158.23KB	Share
ACR	Change of Director's Interest Notice		26/02/18	156.56KB	Share
ACR	Correction Half-Year Financial Report 31 December 2017		23/02/18	1.29MB	Share
ACR	Investor Presntation		20/02/18	1.33MB	Share
ACR	Appendix 4D and Half-Year Report to 31 December 2017	PRICE SENSITIVE	20/02/18	1.23MB	Share
ACR	Investor Conference Call December 2017 Half Year Results		12/02/18	126.09KB	Share
ACR	Axiron Net Sales Quarter to December 2017	PRICE SENSITIVE	01/02/18	331.65KB	Share
ACR	Appendix 3B		29/01/18	931.84KB	Share
ACR	Axiron Patents Appeal Decision	PRICE SENSITIVE	23/11/17	331.46KB	Share
ACR	Appendix 3B		14/11/17	927.79KB	Share
ACR	2017 AGM Results		26/10/17	408.21KB	Share
ACR	2017 AGM Script		26/10/17	376.59KB	Share
ACR	2017 AGM Presentation		26/10/17	2.26MB	Share
ACR	Axiron Net Sales Quarter to September 2017	PRICE SENSITIVE	25/10/17	331.93KB	Share
ACR	Acrux 2017 Annual Report		22/09/17	3.5MB	Share
ACR	Notice of 2017 Annual General Meeting, Proxy Form and OEP		22/09/17	757.08KB	Share
ACR	Axiron License Agreement Terminated	PRICE SENSITIVE	06/09/17	335.33KB	Share
ACR	Axiron Patent Appeal Hearing Date		24/08/17	328.51KB	Share
ACR	Appendix 4G		22/08/17	800.95KB	Share
ACR	2017 Full Year Results Presentation		22/08/17	990.42KB	Share
ACR	Appendix 4E and 2017 Financial Report	PRICE SENSITIVE	22/08/17	1.93MB	Share
ACR	Investor Conference Call 2017 Annual Results		22/08/17	257.51KB	Share
ACR	Teva Launches Generic Version of Axiron in United States	PRICE SENSITIVE	21/08/17	328.43KB	Share
ACR	Axiron Net Sales Quarter to 30 June 2017	PRICE SENSITIVE	26/07/17	338.45KB	Share
ACR	Acrux Presents At Bioshares Biotech Summit		24/07/17	1.2MB	Share
ACR	Axiron Generic Launched In The United States	PRICE SENSITIVE	06/07/17	332.87KB	Share
ACR	Institution of IPR Proceeding Against Key Jublia Patent	PRICE SENSITIVE	02/05/17	428.23KB	Share
ACR	Axiron Net Sales Quarter to 31 March 2017	PRICE SENSITIVE	26/04/17	338.15KB	Share
ACR	S&P DJ Indices Announces March Quarterly Rebalance	PRICE SENSITIVE	10/03/17	177.37KB	Share
ACR	Ceasing to be a substantial holder		28/02/17	137.87KB	Share
ACR	Investor Presentation		17/02/17	1.19MB	Share
ACR	Appendix 4D and Half Year Report to 31 December 2016	PRICE SENSITIVE	17/02/17	1.59MB	Share
ACR	Investor Call December 16 HY Results Updated Dial-In Details		14/02/17	264.28KB	Share
ACR	Change in substantial holding		03/02/17	142.3KB	Share
ACR	Change in substantial holding		01/02/17	144.12KB	Share
ACR	Axiron Net Sales, Quarter to December2016	PRICE SENSITIVE	01/02/17	336.85KB	Share
ACR	Appendix 3B		30/01/17	3.64MB	Share
ACR	Half-Year Results Investor Conference Call		25/01/17	263.64KB	Share
ACR	Change in substantial holding		19/01/17	148.84KB	Share
ACR	Final Director Interest Notice		08/12/16	221.85KB	Share

ACR Company Update - COVID-19
20/03/20		149.91KB	Share
ACR Change of Director's Interest Notice
16/03/20		472.7KB	Share
ACR Appendix 2A
16/03/20		333.56KB	Share
ACR Appendix 4D and Half Year Financial Report
25/02/20	PRICE SENSITIVE	982.5KB	Share
ACR Change of Director's Interest Notice
17/02/20		250.33KB	Share
ACR Appendix 2A
17/02/20		336.72KB	Share
ACR Appendix 3G
04/02/20		339.47KB	Share
ACR Appendix 2A
04/02/20		336.31KB	Share
ACR Change of Director's Interest Notice
15/01/20		249.94KB	Share
ACR Appendix 3B
15/01/20		525.04KB	Share
ACR Appendix 3B
16/12/19		523.62KB	Share
ACR Change of Director's Interest Notice
09/12/19		537.7KB	Share
ACR Appendix 3B
09/12/19		526.67KB	Share
ACR Initial Director's Interest Notice
28/11/19		215.21KB	Share
ACR Final Director's Interest Notice
28/11/19		150.02KB	Share
ACR Annual General Meeting Results
28/11/19		139.75KB	Share
ACR Acrux Investor Presentation
28/11/19		702.05KB	Share
ACR Acrux AGM Script
28/11/19		205.14KB	Share
ACR Receipt of second R&D Tax Incentive Rebate
06/11/19		134.42KB	Share
ACR 2019 Notice of Annual General Meeting
25/10/19		3.22MB	Share
ACR Receipt of first R&D Tax Incentive Rebate
24/10/19	PRICE SENSITIVE	135.27KB	Share
ACR Presentation - Australian Microcap Investment Conference
22/10/19		875.88KB	Share
ACR Change of Director's Interest Notice
07/10/19		195.27KB	Share
ACR Change of Director's Interest Notice
03/10/19		195.82KB	Share
ACR Change of Director's Interest Notice
24/09/19		195.45KB	Share
ACR Annual Report to shareholders
24/09/19		2.09MB	Share
ACR Notice Received Under S249N of the Corporations Act
23/09/19		135.75KB	Share
ACR Change of Director's Interest Notice
10/09/19		195.63KB	Share
ACR Acrux Ltd Investor Presentation and Full Year Results
26/08/19	PRICE SENSITIVE	713.5KB	Share
ACR Appendix 4G and Corporate Governance Statement
23/08/19		722.47KB	Share
ACR Appendix 4E & Full Year Statutory Accounts
23/08/19	PRICE SENSITIVE	2.44MB	Share
ACR Acrux's third generic dossier accepted by FDA for review
19/08/19		216.36KB	Share
ACR Appendix 3B
15/08/19		1.16MB	Share
ACR Investor Presentation - Bioshares Summit
29/07/19		906.5KB	Share
ACR Appendix 3B
17/06/19		1.13MB	Share
ACR Change in Company Secretary
07/06/19		140.02KB	Share
ACR Jublia Patent Litigation Settlement
03/04/19	PRICE SENSITIVE	123.89KB	Share
ACR Becoming a substantial holder
28/02/19		156.57KB	Share
ACR Investor Presentation
25/02/19	PRICE SENSITIVE	837.85KB	Share
ACR Appendix 4D and Half-Year Financial Report to 31 Dec 2018
21/02/19	PRICE SENSITIVE	965.44KB	Share
ACR Appendix 3B
18/02/19		383.01KB	Share
ACR Appendix 3B
05/02/19		385.91KB	Share
ACR Acrux Receives $2.057m R&D Tax Incentive Rebate
21/01/19	PRICE SENSITIVE	106.75KB	Share
ACR End of Year Update
20/12/18		361.75KB	Share
ACR Appendix 3B
23/11/18		384.11KB	Share
ACR Change of Director's Interest Notice
13/11/18		157.25KB	Share
ACR 2018 AGM Results
01/11/18		144.16KB	Share
ACR 2018 AGM Script
01/11/18		143.89KB	Share
ACR 2018 AGM Presentation
01/11/18		837.15KB	Share
ACR Change of Director's Interest Notice
19/10/18		156.7KB	Share
ACR Acrux has second generic dossier accepted for review by FDA
17/10/18	PRICE SENSITIVE	215.94KB	Share
ACR Acrux confirms patent challenge for generic of efinaconazole
24/09/18	PRICE SENSITIVE	157.3KB	Share
ACR Notice of 2018 Annual General Meeting/Proxy Form
21/09/18		336.5KB	Share
ACR 2018 Annual Report
21/09/18		2.69MB	Share
ACR Updated Acrux Investor Presentation
18/09/18		1.06MB	Share
ACR 2018 Annual Results and Investor Presentation
16/08/18		1.1MB	Share
ACR Appendix 4G
16/08/18		572.42KB	Share
ACR Appendix 4E and 2018 Financial Report
16/08/18	PRICE SENSITIVE	1.44MB	Share
ACR Investor Conference Call 2018 Annual Results
14/08/18		105.31KB	Share
ACR Acrux Submits First-To-File Generic of Jublia
02/08/18	PRICE SENSITIVE	202KB	Share
ACR Becoming a substantial holder
10/04/18		158.23KB	Share
ACR Change of Director's Interest Notice
26/02/18		156.56KB	Share
ACR Correction Half-Year Financial Report 31 December 2017
23/02/18		1.29MB	Share
ACR Investor Presntation
20/02/18		1.33MB	Share
ACR Appendix 4D and Half-Year Report to 31 December 2017
20/02/18	PRICE SENSITIVE	1.23MB	Share
ACR Investor Conference Call December 2017 Half Year Results
12/02/18		126.09KB	Share
ACR Axiron Net Sales Quarter to December 2017
01/02/18	PRICE SENSITIVE	331.65KB	Share
ACR Appendix 3B
29/01/18		931.84KB	Share
ACR Axiron Patents Appeal Decision
23/11/17	PRICE SENSITIVE	331.46KB	Share
ACR Appendix 3B
14/11/17		927.79KB	Share
ACR 2017 AGM Results
26/10/17		408.21KB	Share
ACR 2017 AGM Script
26/10/17		376.59KB	Share
ACR 2017 AGM Presentation
26/10/17		2.26MB	Share
ACR Axiron Net Sales Quarter to September 2017
25/10/17	PRICE SENSITIVE	331.93KB	Share
ACR Acrux 2017 Annual Report
22/09/17		3.5MB	Share
ACR Notice of 2017 Annual General Meeting, Proxy Form and OEP
22/09/17		757.08KB	Share
ACR Axiron License Agreement Terminated
06/09/17	PRICE SENSITIVE	335.33KB	Share
ACR Axiron Patent Appeal Hearing Date
24/08/17		328.51KB	Share
ACR Appendix 4G
22/08/17		800.95KB	Share
ACR 2017 Full Year Results Presentation
22/08/17		990.42KB	Share
ACR Appendix 4E and 2017 Financial Report
22/08/17	PRICE SENSITIVE	1.93MB	Share
ACR Investor Conference Call 2017 Annual Results
22/08/17		257.51KB	Share
ACR Teva Launches Generic Version of Axiron in United States
21/08/17	PRICE SENSITIVE	328.43KB	Share
ACR Axiron Net Sales Quarter to 30 June 2017
26/07/17	PRICE SENSITIVE	338.45KB	Share
ACR Acrux Presents At Bioshares Biotech Summit
24/07/17		1.2MB	Share
ACR Axiron Generic Launched In The United States
06/07/17	PRICE SENSITIVE	332.87KB	Share
ACR Institution of IPR Proceeding Against Key Jublia Patent
02/05/17	PRICE SENSITIVE	428.23KB	Share
ACR Axiron Net Sales Quarter to 31 March 2017
26/04/17	PRICE SENSITIVE	338.15KB	Share
ACR S&P DJ Indices Announces March Quarterly Rebalance
10/03/17	PRICE SENSITIVE	177.37KB	Share
ACR Ceasing to be a substantial holder
28/02/17		137.87KB	Share
ACR Investor Presentation
17/02/17		1.19MB	Share
ACR Appendix 4D and Half Year Report to 31 December 2016
17/02/17	PRICE SENSITIVE	1.59MB	Share
ACR Investor Call December 16 HY Results Updated Dial-In Details
14/02/17		264.28KB	Share
ACR Change in substantial holding
03/02/17		142.3KB	Share
ACR Change in substantial holding
01/02/17		144.12KB	Share
ACR Axiron Net Sales, Quarter to December2016
01/02/17	PRICE SENSITIVE	336.85KB	Share
ACR Appendix 3B
30/01/17		3.64MB	Share
ACR Half-Year Results Investor Conference Call
25/01/17		263.64KB	Share
ACR Change in substantial holding
19/01/17		148.84KB	Share
ACR Final Director Interest Notice
08/12/16		221.85KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.8¢		Change 0.000(0.00%)		Mkt cap ! $7.366M

Open	High	Low	Value	Volume
1.8¢	1.8¢	1.8¢	$5.04K	280K

Buyers (Bids)

No.	Vol.	Price($)
6	916823	1.7¢

Sellers (Offers)

Price($)	Vol.	No.
1.9¢	265520	1

View Market Depth

No.	Vol.	Price($)
6	916823	0.017
11	1275173	0.016
6	1361882	0.015
2	140000	0.014
3	486850	0.013

Price($)	Vol.	No.
0.019	265520	1
0.020	56617	4
0.021	584213	2
0.022	100000	1
0.023	381179	1

Last trade - 14.14pm 29/07/2025 (20 minute delay)


Last 1.8¢		Change 0.000 ( 5.26 %)
Open	High	Low	Volume
1.8¢	1.8¢	1.8¢	53130
Last updated 11.05am 29/07/2025 ?

ACR (ASX) Chart

ACRUX LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available